Pain Management

 
Obesity and Chronic Pain: Monu Khanna, MD, on Breaking the Vicious Cycle
July 10, 2025

Dr Khanna breaks down the bidirectional relationship and explains why standard pain management often falls short for people with obesity.

Pain Management in Patients with Obesity: Clinician Insights on Balancing Pharmacological & Lifestyle Approaches
July 09, 2025

Monu Khanna, MD, discusses common medications, non-drug strategies, and holistic approaches to improve outcomes.

Monu Khanna, MD: Practical Pain Management Tips for Patients with Obesity
July 08, 2025

Dr Khanna discusses dosing challenges, metabolic issues, and potential complications from medications like acetaminophen.

8 Common Myths About Chronic Back Pain, Plus 8 Facts That Refute Them
July 01, 2025

Back pain is more common in the US than homeownership, but despite the prevalence, myths persist regarding origins, treatment, and prevention. Here are 8 of them.

IV Ibuprofen Cuts Postop Opioid Use by 23% in Older Adults, Study Finds
May 28, 2025

The opioid-sparing IVIB pain management strategy in adults aged 60 and older was effective in the immediate post-surgical period and associated with limited AEs.

ACOG Issues Consensus Guidance to Improve Pain Control During In-Office Gynecologic Procedures
May 16, 2025

Every patient should be offered evidence-based analgesia for pain management for in-office uterine and cervical procedures after shared, trauma-informed decision-making.

Depression & Anxiety in Adults with Chronic Pain: A Meta-Analysis Review
April 28, 2025

Approximately 40% of adults with chronic pain have comorbid anxiety and/or depression, underscoring the importance of routine screening in this population.

FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update
March 13, 2025

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.

Nonopioid Analgesic Pilavapadin Advances to Phase 3 for Diabetic Neuropathy
March 03, 2025

The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.

FDA Approves Expanded Use for Sublocade for Opioid Use Disorder
February 24, 2025

These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.